COMPARISON OF CARDIOMETABOLIC OUTCOMES BETWEEN GLP-1 AGONISTS AND BARIATRIC SURGERY IN PATIENTS WITH METABOLIC SYNDROME

Abstract

Metabolic syndrome is a set of interrelated metabolic disorders, including abdominal obesity, dyslipidemia, arterial hypertension and insulin resistance, which significantly increase the risk of cardiovascular disease and type 2 diabetes. Given this scenario, the search for effective therapeutic strategies is essential to control risk factors and improve patients' quality of life. This article aims to compare the cardiometabolic outcomes of the use of GLP-1 receptor agonists (GLP-1RAs) with those of bariatric surgery in individuals with metabolic syndrome. Through a review of recent literature, it was observed that both treatments promote relevant clinical benefits, with bariatric surgery showing a greater short-term impact on weight loss and remission of type 2 diabetes, while GLP-1RAs offer a less invasive profile with sustained favorable effects. It is concluded that the therapeutic choice should consider individual factors, such as severity of the condition, associated comorbidities, patient preferences and access to treatment, reinforcing the importance of a multidisciplinary and personalized approach.